Japan’s Shionogi sees COVID-19 pill reaping US$2 billion in annual sales upon US approval
TOKYO: Japan’s Shionogi & Co believes its COVID-19 pill will easily garner US$2 billion in annual sales if it secures US approval, which the company expects to receive in late 2024, its chief executive said. Xocova, a protease inhibitor like the COVID-19 treatments developed by Pfizer and Merck & Co,Continue Reading